With delayed review date looming, Bristol Myers uncorks more winning data for blockbuster-potential heart drug
Bristol Myers Squibb doled out a whopping $13 billion for MyoKardia back in late 2020, mainly on the blockbuster hopes of heart drug mavacamten. Despite some winning late-stage data, the drug has seen nothing but delays — but another big win could put some wind in Bristol Myers’ sails as a key review date approaches.
On Wednesday, Bristol Myers revealed topline data from the Phase III VALOR-HCM trial showing mavacamten bested placebo in reducing the need for an invasive procedure in patients with obstructive hypertrophic cardiomyopathy (oHCM), the drug giant said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.